Jasper Therapeutics, Inc. - Class A (JSPR)
JSPR moved a median of -0.48% 30 minutes after news, and -0.42% by the close. How JSPR actually reacts to news — the realized, point-in-time move the market made, measured across 722 labeled events over the last three years with zero look-ahead.
JSPR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.07% | 35% | 701 |
| 30-min | -0.48% | 34% | 719 |
| 60-min | -0.53% | 39% | 719 |
| to close | -0.42% | 45% | 713 |
| Middle 50% of JSPR reactions | -1.98% to +0.70% |
|---|---|
| Median reaction (30-min) | -0.48% |
| Measured reactions | 722 |
Half of all Jasper Therapeutics, Inc. - Class A news events land between -1.98% and +0.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How JSPR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 13 | +0.16% | 69% | -2.89% |
| Coverage initiations | 36 | -0.54% | 28% | -2.20% |
| Rating reiterations | 52 | +0.16% | 58% | +0.17% |
| Price-target cuts | 15 | -0.37% | 40% | -1.67% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how JSPR ranks against every other measured name →
That’s how JSPR usually reacts — get an email when it moves on news →Email me when JSPR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JSPR's baseline. Nothing else.
Recent JSPR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A Jasper Therapeutics, For: Nov 13 | SEC filing · Form DEF | SEC EDGAR | -3.89% | — | |
| Form 8-K Jasper Therapeutics, For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +3.16% | +8.59% | |
| Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy | Press release | GlobeNewswire | +3.16% | +8.59% | |
| Form S-3 Jasper Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +3.16% | +8.59% | |
| Form PRE 14A Jasper Therapeutics, For: Oct 09 | SEC filing · Form PRE | SEC EDGAR | +0.02% | -2.43% | |
| Form 8-K Jasper Therapeutics, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | +4.86% | |
| Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants | Press release | GlobeNewswire | -0.50% | +4.86% | |
| Form 8-K Jasper Therapeutics, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | +4.00% | |
| Form 8-K/A Jasper Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | +4.00% | |
| Form 8-K/A Jasper Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | -8.10% | |
| Form 8-K Jasper Therapeutics, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -3.06% | -2.51% | |
| Jasper Therapeutics Announces Key Regulatory and Clinical Appointments | Press release | GlobeNewswire | +1.09% | +0.71% | |
| Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.58% | +0.01% | |
| Form DEF 14A Jasper Therapeutics, For: Sep 30 | SEC filing · Form DEF | SEC EDGAR | -0.21% | +1.99% | |
| Form 8-K Jasper Therapeutics, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +1.20% | -1.03% | |
| Form PRE 14A Jasper Therapeutics, For: Aug 24 | SEC filing · Form PRE | SEC EDGAR | -1.38% | +1.65% | |
| Form 10-Q Jasper Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.45% | -5.51% | |
| Form 8-K Jasper Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +4.42% | +9.38% | |
| Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.63% | -5.50% | |
| Form D Jasper Therapeutics, | SEC filing · Form D | SEC EDGAR | -5.32% | -0.84% | |
| Form 8-K Jasper Therapeutics, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +9.10% | |
| Form 8-K Jasper Therapeutics, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -4.75% | +0.00% | |
| Form 8-K Jasper Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -6.03% | +23.00% | |
| Form 8-K Jasper Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -6.03% | +23.00% | |
| Jasper Therapeutics Announces Merger with Kira Pharmaceuticals | Press release | GlobeNewswire | -6.03% | +23.00% | |
| Form ARS Jasper Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.30% | -3.77% | |
| Form DEF 14A Jasper Therapeutics, For: Jul 31 | SEC filing · Form DEF | SEC EDGAR | -1.30% | -3.77% | |
| Form DEFA14A Jasper Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.30% | -3.77% | |
| Form 8-K Jasper Therapeutics, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | +4.10% | |
| Form 8-K Jasper Therapeutics, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -34.86% | |
| Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value | Press release | GlobeNewswire | -0.01% | -34.86% | |
| Form 8-K Jasper Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +2.61% | |
| Form 10-Q Jasper Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.11% | -7.20% | |
| Form 8-K Jasper Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | -7.20% | |
| Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.11% | -7.20% | |
| Form 10-K/A Jasper Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.41% | -1.01% | |
| Form 10-K Jasper Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.62% | +2.44% | |
| Form 8-K Jasper Therapeutics, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +3.62% | +2.44% | |
| Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.62% | +2.44% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.81% | -5.07% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.38% | +0.76% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -1.49% | +0.75% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -1.79% | |
| Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference | Press release | GlobeNewswire | -1.07% | +0.00% | |
| Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.37% | +2.24% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +1.66% | +0.41% | |
| Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.85% | +4.31% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -4.49% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -2.60% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.87% | +1.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the JSPR section they belong to.
Where else JSPR is measured.
JSPR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Jasper Therapeutics, Inc. - Class A's median reaction calculated?
Every labeled JSPR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 722 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of JSPR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does JSPR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.